The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06103058

Enrollment

965

Registered

2023-10-26

Start date

2023-05-12

Completion date

2024-12-31

Last updated

2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia, Orthopedic Disorder

Brief summary

Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan. The city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. The study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. Accurate prevalence data aids healthcare planning and resource allocation.

Interventions

OTHERCross sectional

Cross sectional

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

1 Months to 100 Years

Healthy volunteers

Yes

Inclusion criteria

Using google forms, this cross-sectional study was carried out, and the participants were reached via social media platforms (5) . Participants' autonomy was maintained, and no direct benefit was gained in return for filling out the questionnaire. The ethics committee at the Faculty of Medicine, Mutah University, Karak, Jordan, provided the required ethical approval prior to the initiation of this study. Moreover, the committee ensured that the study was designed according to the principles of the Declaration of Helsinki (Date: 13 February 2023. Reference number: 992023). In this study, the authors targeted Karak government citizens, in Jordan. Accordingly, the required sample size to achieve a 99% Confidence interval was 663 participants.

Design outcomes

Primary

Measure	Time frame	Description
Cross sectional	2 years	Outcome measurements

Countries

Jordan

Contacts

Primary ContactMohammad Abu-Jeyyab, MD

mabujeyyab@yahoo.com+962796383747

Backup ContactAlaa Akel, MD

alaaakel@mutah.edu.jo0796383747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026